[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352774-105":59,"doc-detail-352774-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gpa33-forms-a-distinct-diagnostic-target-class-to-claudin-182-in-oesophageal-adenocarcinoma-enabling-the-development-of-a-novel-gpa33-antibody-based-detection-platform","GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform","","Oesophageal adenocarcinoma (OAC) remains a cancer with high unmet clinical need, likely comprising molecularly distinct subtypes. Claudin 18.2 antibodies are emerging therapeutics, while proteogenomics identified glycoprotein A33 (GPA33) as a dominant cancer-specific target. This study tests whether GPA33 is distinct from, or overlaps with, Claudin 18.2 as a theranostic target in OAC. Using patient microarrays and scFv-phage display, GPA33 shows superior tumor specificity and largely mutually exclusive expression with Claudin 18.2, enabling GPA33-based diagnostics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gpa33-forms-a-distinct-diagnostic-target-class-to-claudin-182-in-oesophageal-adenocarcinoma-enabling-the-development-of-a-novel-gpa33-antibody-based-detection-platform/352774/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gpa33-forms-a-distinct-diagnostic-target-class-to-claudin-182-in-oesophageal-adenocarcinoma-enabling-the-development-of-a-novel-gpa33-antibody-based-detection-platform/352774.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about GPA33 and Claudin 18.2 in OAC?","Question",{"text":112,"@type":113},"The study determines whether GPA33 is distinct from or overlaps with Claudin 18.2 as a theranostic diagnostic target in oesophageal adenocarcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were GPA33 and Claudin 18.2 expression patterns compared in the study?",{"text":117,"@type":113},"A microarray from 106 patients was used to compare expression of GPA33 and Claudin 18.2 across cancer tissue, normal squamous tissue, normal gastric tissue, and metastatic lymph nodes.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic potential does GPA33 show relative to Claudin 18.2?",{"text":121,"@type":113},"GPA33 shows elevated cancer-specific expression and generally mutually exclusive expression with Claudin 18.2, defining a Claudin 18.2-negative patient class and supporting novel diagnostic tool development.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352774,1790640338,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Brydon et al. Cellular & Molecular Biology Letters (2026) 31:58 [https://doi.org/10.1186/s11658-025-00852-1](https://doi.org/10.1186/s11658-025-00852-1)  \nCellular & Molecular Biology Letters  \nRESEARCH Open Access  \nGPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform  \nJack Brydon 1†, Radovan Krejcir2†, Filip Zavadil-Kokas2, Ashita Singh 1, Tomas Henek2, Lenka Hernychova2,  \nSkye Coleman 1, Sofian Al Shboul3, Vaclav Hrabal2, Zuzana Kuncova2, Marcos Yébenes Mayordomo4,  \nŁukasz Arcimowicz2, Kathryn L. Ball 1, Monikaben Padariya4, Umesh Kalathiya4, Borivoj Vojtesek2,5*, Ted Hupp 1,4* and J. R. O’Neill6,7*  \n†Jack Brydon and Radovan Krejcir are joint first authors.  \n*Correspondence: Borivoj Vojtesek[vojtesek@mou.cz](vojtesek@mou.cz)[ ](vojtesek@mou.cz)Ted Hupp [ted.hupp@ed.ac.uk](ted.hupp@ed.ac.uk)  \nJ. R. O’Neill [robertoneill@nhs.net](robertoneill@nhs.net)  \nFull list of author information is available at the end of the article  \nAbstract  \nBackground Oesophageal adenocarcinoma (OAC) is a cancer of high unmet clinical need. Because of tumour heterogeneity, it is likely that OAC will be stratified into several subtypes. Claudin 18.2 antibodies form emerging novel therapeutics inpatients with a subtype of OAC. A large-scale proteogenomics screen in OAC identified glycoprotein A33 (GPA33) protein as a dominating cancer-specific target. We set out to determine whether GPA33 is distinct from or overlaps with Claudin 18.2 as atheranostic target in OAC.  \nMethods A microarray from n = 106 patients, composed of cancer, normal squamoustissue, normal gastric tissue, and metastatic lymph nodes, was used to compare the expression of GPA33 and Claudin 18.2. A single-chain variable fragment (scFv)-phage display library was screened against recombinant GPA33 protein to isolate novel monoclonal antibodies. Next-generation complementarity-determining region 3 (CDR3) DNA sequencing (NGS) and enzyme-linked immunosorbent assay (ELISA) were both used to measure efficacy of antibody enrichment during biopanning.  \nResults GPA33 exhibits superior tumour-specific expression compared with Claudin 18. 2, the latter of which is expressed in normal gastric tissue. GPA33 and Claudin 18.2 exhibit statistically significant mutually exclusive expression in cancer tissue cores; 36% of cancers are GPA33+/Claudin 18.2 − , whilst 22% are GPA33 −/Claudin 18.2+ . GPA33 therefore forms a novel target for theranostics in a significant number of patients. A monoclonal antibody (RSE-05) targeting GPA33 was isolated from a scFV-phage display library. The antibody required a di-sulphide bridge to maintain its epitope on the antigen. Epitope mapping was performed using di-sulphide bridge mutagenesis, peptide-phage display, and XL-MS. The dominant epitope resides in the V-type IgG  \n© Crown 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nBrydon et al. Cellular & Molecular Biology Letters (2026) 31:58 Page 2 of 36  \ndomain of GPA33 at residues 27–29 and structural amino acids S17 and K65 . This  \ndi-sulphide bridge-constrained epi","cbCairJH4s8lATnH","https://ap.wps.com/l/cbCairJH4s8lATnH","pdf",4604526,36,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords","[{\"question\":\"What question does the study address about GPA33 and Claudin 18.2 in OAC?\",\"answer\":\"The study determines whether GPA33 is distinct from or overlaps with Claudin 18.2 as a theranostic diagnostic target in oesophageal adenocarcinoma.\"},{\"question\":\"How were GPA33 and Claudin 18.2 expression patterns compared in the study?\",\"answer\":\"A microarray from 106 patients was used to compare expression of GPA33 and Claudin 18.2 across cancer tissue, normal squamous tissue, normal gastric tissue, and metastatic lymph nodes.\"},{\"question\":\"What diagnostic potential does GPA33 show relative to Claudin 18.2?\",\"answer\":\"GPA33 shows elevated cancer-specific expression and generally mutually exclusive expression with Claudin 18.2, defining a Claudin 18.2-negative patient class and supporting novel diagnostic tool development.\"}]","GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform | PDF",1790101342,91,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51ca6b7ce5dea79b0ed2d5ae19532e0b.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71c455d5b092cc3e5b2aaddcdd418779.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c316f0aafdb53954ca0066d16546f758.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09ef3a3da24b9becfecc2f48b330c184.webp",980,1306]